I’d start with their balance sheet... over US$120m cash but they have around US$90 in debt. So not much room to move in that sense... any major delays will mean more capital required.
the key delay could be (not likely) a knock back from the FDA on Ryoncil.. that decision is due no later than 30 Sept.
there are some phase 3 trials (back pain, CHF and COVID)due to read out before years end.. if they fail, then that will mean the share price will go down..
Overwhelming efficacy - the stats required, page-314
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.030(2.87%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.09 | $1.04 | $6.705M | 6.294M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4699 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 15.59pm 11/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.030 ( 4.03 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.09 | $1.04 | 1031073 | ||
| Last updated 15.59pm 11/06/2024 ? | |||||
| MSB (ASX) Chart |